TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04356352

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaine
Description: 1 mg/kg lidocaine to a max of 100 mg administered approximately 30 seconds prior to the administration of propofol, with pain score obtained before the propofol is administered.
Study: NCT02502266

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olaparib
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olaparib
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olaparib
Description: Given PO

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel
Description: Given IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel
Description: Given IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pegylated Liposomal Doxorubicin Hydrochloride
Description: Given IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pegylated Liposomal Doxorubicin Hydrochloride
Description: Given IV

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Topotecan
Description: Given IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Topotecan
Description: Given IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Topotecan Hydrochloride
Description: Given IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Topotecan Hydrochloride
Description: Given IV
Study: NCT01716013

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BondEase
Description: topical skin adhesive

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: CWCD
Description: traditional closure methods of sutures, staples or adhesive strips
Study: NCT04409288

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apalutamide
Description: Androgen receptor inhibitor.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apalutamide
Description: Androgen receptor inhibitor.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enzalutamide
Description: Androgern receptor inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enzalutamide
Description: Androgern receptor inhibitor
Study: NCT03318991

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Laser prostatectomy
Description: Patients with symptomatic benign prostate obstruction (BPO) will be assigned under randomisation to treat with GreenLight laser or thulium laser.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Laser prostatectomy
Description: Patients with symptomatic benign prostate obstruction (BPO) will be assigned under randomisation to treat with GreenLight laser or thulium laser.
Study: NCT00771433

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: filgrastim
Description: Given subcutaneously

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: filgrastim
Description: Given subcutaneously
Study: NCT05256121

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: AD Risk factors balance
Description: At baseline, participants in the intervention group will be asked to fill a daily risk-factor diaries (Risk factors log using the REDCap (Research Electronic Data Capture) software's survey).~In the Risk factors log, participants will need to answer shortly questions about their specific unbalanced risk factor.~In addition, during the 18-months intervention period, the study team will communicate with the participants by phone every 3-4 weeks to inquire about risk factors data. Before each phone call, participants' Risk factors log data since previous phone call will be analyzed. The team will propose alternative activities, and provide positive reinforcement and feedback.
Study: NCT02188810

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: TIV
Description: Single dose administered intramuscularly .
Study: NCT04113499

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Direct Endoscopic Intervention
Description: The necrotic collection is first identified using a linear echoendoscope. A Hot AXIOS stent is utilized in all patients for EUS-guided drainage of the necrotic collection. The necrotic material is sent for gram stain and culture with sensitivities.~For endoscopic necrosectomy, in patients allocated to direct endoscopic necrosectomy group, endoscopic necrosectomy is performed during the same session as the index endoscopic drainage. It is performed using a therapeutic gastroscope and various accessories (see below for further details) for 90 to 120 minutes.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Step-up Endoscopic Intervention
Description: The necrotic collection is first identified using a linear echoendoscope. A Hot AXIOS stent is utilized in all patients for EUS-guided drainage of the necrotic collection. The necrotic material is sent for gram stain and culture with sensitivities.~In patients allocated to the step-up endoscopic interventions group, endoscopic necrosectomy is not performed at the time of the index intervention, however it is performed when clinically indicated during the follow-up period (6 months from index intervention).
Study: NCT01138280

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CWP 103H (Gambro, Sweden): a heat disinfection device
Description: Heat disinfection can increase temperature to 95c in the RO water treatment system and then in the piping system link to dialysis machines in each hemodialysis center per night
Study: NCT03090100

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Guselkumab
Description: Participants will receive 1 injection of active guselkumab at Weeks 0, 4, 12, 20, 28, 36, and 44.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Participants will receive 1 injection of placebo at Weeks 0, 4, 12, 20, 28, 36, and 44 and 2 injections of placebo at Weeks 1, 2, 3, 8, 16, 24, 32, and 40.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Secukinumab
Description: Participants will receive 2 injections of active secukinumab at Weeks 0, 1, 2, 3, 4 and every 4 weeks (q4w) thereafter through Week 44.
Study: NCT03209492

Intervention type: DRUG
Intervention: Leuprorelin acetate
Description: Leuplin PRO for Injection Kit 22.5 mg
Study: NCT02188810

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TIV
Description: Single dose administered intramuscularly .

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TIV
Description: Single dose administered intramuscularly .

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TIV
Description: Single dose administered intramuscularly .

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TIV
Description: Single dose administered intramuscularly .

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TIV
Description: Single dose administered intramuscularly .
Study: NCT01889147

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: hRESCAP
Description: one acute bolus administration of different dosages of hRESCAP (microdose, part 1; and FIH: low dose, 414 µg; medium dose, 2480 µg; high dose, 5300 µg; part 2)

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: hRESCAP
Description: one acute bolus administration of different dosages of hRESCAP (microdose, part 1; and FIH: low dose, 414 µg; medium dose, 2480 µg; high dose, 5300 µg; part 2)

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT03857815

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: anti-PD-1 antibody
Description: In patients with inoperable hepatocellular carcinoma or recurrence after local or regional therapy, stereotactic body radiation therapy will be combined with anti-PD-1 antibody.~Stereotactic body radiation therapy: SBRT is delivered to 1\~5 Evaluable lesions of liver, lung, bone, brain or lymph nodes in limited fractions .~Anti-PD-1 treatment: anti-PD-1 antibody (IBI308) is injected intravenously 200mg every three weeks.
Study: NCT01259271

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Selective Nerve Stimulation (SNS) stimulator device
Description: Two hours per study visit separated by a minimum of a 20 hour wash out period between stimulations.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Selective Nerve Stimulation (SNS) stimulator device
Description: Two hours per study visit separated by a minimum of a 20 hour wash out period between stimulations.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Selective Nerve Stimulation (SNS) stimulator device
Description: Two hours per study visit separated by a minimum of a 20 hour wash out period between stimulations.
Study: NCT03536741

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: TAP block and RS block + General Intravenous Anesthestic
Description: transversus abdominis plane block and rectus sheath block
Study: NCT00621842

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lamotrigine regular tablet formulation
Description: Day 0 lamotrigine regular tablet formulation or lamotrigine novel formulation will be initiated at 25 mg/day and upward titrated as per package insert to targeted maximum dose of 200 mg/day. Dosing will be reduced for individuals who experience adverse effects. Dosing will be modified as per package insert for lamotrigine for individuals on anticonvulsant compounds.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lamotrigine novel formulation
Description: Participants will have the option of trying a novel formulation of lamotrigine tablets instead of the lamotrigine regular formulation tablets. The dosing will remain the same regardless of which type of lamotrigine tablet is used.~Day 0 lamotrigine regular tablet formulation or lamotrigine novel formulation will be initiated at 25 mg/day and upward titrated as per package insert to targeted maximum dose of 200 mg/day. Dosing will be reduced for individuals who experience adverse effects. Dosing will be modified as per package insert for lamotrigine for individuals on anticonvulsant compounds.
Study: NCT03136588

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Feedback using ICT based monitoring system
Description: In case of a missed immunosuppressant dose, the first violation does not generate a feedback while the second one does within one hour at the break of the ±3 hour range from the fixed dosing time. Up to two additional alarms/texts are sent at an interval of 30 minutes if the dose is still not taken after the feedback. For any discrepancy between the dosage taken and the dosage prescribed, a feedback is sent within 1 hour from the moment of recognition. Again, the first violation goes without response, while any violation after that generates feedbacks. Similarly, if a dose is taken outside of the allowed ±3 hour dosing time range, a feedback is sent within 1 hour of recognition, starting with the second violation.
Study: NCT01878539

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: coagulometer

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: training programme
Study: NCT04356352

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Esmolol
Description: 0.5 mg/kg esmolol to a max of 50mg administered approximately 30 seconds prior to the administration of propofol, with pain score obtained before the propofol is administered.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: saline water administered approximately 30 seconds prior to the administration of propofol, with pain score obtained before the propofol is administered.
Study: NCT03478735

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ultrasound Guided Greater Occipital Nerve Block at C2
Description: Ultrasound guided injection

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Landmark-Based Greater Occipital Nerve Block
Description: Traditional landmark-guided technique at the superior nuchal line. This approach relies solely on superficial bone-based anatomic landmarks to infiltrate local anesthetic and corticosteroid around the nerve at the level of the superior nuchal line.
Study: NCT02846701

Intervention type: DRUG
Group type: OTHER
Intervention: duloxetine
Description: The concentration of duloxetine is measured by liquid chromatography coupled to tandem mass spectrometry on blood sample
Study: NCT06039618

Intervention type: OTHER
Intervention: Referral to Centre of Higher Organizational Level
Description: Referral to Centre of Higher Organizational Level. This means referral from a primary neonatal care center to a secondary one, or from the secondary to the tertiary center.
Study: NCT02610452

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Clown therapy
Description: The clowns intervene by twos: a game takes place.~1. The game requires the active presence of a number of potential players in the room (patient, family, caregivers) and takes into account body position, emotional state, the general atmosphere.~2. The clowns initiate a game proposal: provisional staging of clown characters based on imagination/improvisation which engages a physicality and a basic emotional state.~3. The original game proposal is adjusted according to mutual empathy with those present.~4. The game is developed on the model of theatrical improvisation: an original creation that has scenic quality comparable to that of a complete representation. Improvisation time varies depending on the condition of the person, his/her desire to participate, choosing the main theme.~5. The final stage of the game is preparing all actors for separation: restitution of roles, revisiting the paths traveled.
Study: NCT01371734

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Desvenlafaxine Succinate Sustained-Release
Description: Subjects randomized to DVS SR treatment arm will receive 25, 35, or 50 mg/day based on subject weight at the Baseline visit.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Desvenlafaxine Succinate Sustained-Release
Description: Subjects randomized to DVS SR treatment arm will receive 20, 25, or 35 mg/day based on subject weight at the Baseline visit.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subjects randomized to the Placebo treatment arm will receive placebo tablets
Study: NCT02052401

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Domiciliary Intervention
Description: Two time domiciliary application of an standardized protocol consisting of: a) evaluation of pharmacological and non pharmacological therapies adherence. b) application of a Checklist of home safety measures. c) development of a patient oriented occupational routine d) education in strategies for elderly global stimulation e) education strategies for identifying red flags and for correct use of health services.
Study: NCT03839589

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness Based Stress Reduction Adapated (MBSR-A)
Description: Mindfulness-based stress reduction (MBSR) is a group-based intervention developed in 1979 by Dr. Jon Kabat-Zinn to provide mindfulness training in order to decrease stress and improve overall well-being. MBSR has been shown to be effective for a series of patient outcomes including depression, anxiety disorders, sleep disorders, and chronic pain management. MBSR is a structured intervention delivered through an 8-week course of up to 30 participants who meet for 2.5 hours per week.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Mindfulness Based Stress Reduction Adapated (MBSR-A)
Description: Mindfulness-based stress reduction (MBSR) is a group-based intervention developed in 1979 by Dr. Jon Kabat-Zinn to provide mindfulness training in order to decrease stress and improve overall well-being. MBSR has been shown to be effective for a series of patient outcomes including depression, anxiety disorders, sleep disorders, and chronic pain management. MBSR is a structured intervention delivered through an 8-week course of up to 30 participants who meet for 2.5 hours per week.
Study: NCT03595410

Intervention type: OTHER
Intervention: Recurrence laryngeal cancer
Description: Recurrence laryngeal cancer has a wide range of invasion, rapid progression and poor prognosis.

Intervention type: OTHER
Intervention: Recurrence laryngeal cancer
Description: Recurrence laryngeal cancer has a wide range of invasion, rapid progression and poor prognosis.
Study: NCT01217970

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibudilast 20mg
Description: Ibudilast 20mg BID

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibudilast 20mg
Description: Ibudilast 20mg BID

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibudilast 50mg
Description: Ibudilast 50mg BID

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibudilast 50mg
Description: Ibudilast 50mg BID

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo oral tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo oral tablet
Study: NCT02312232

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: levodopa, carbidopa, ODM-104

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: levodopa, carbidopa, ODM-104

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: levodopa, carbidopa, ODM-104

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: levodopa, carbidopa, ODM-104

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: levodopa, carbidopa, ODM-104
Study: NCT01847391

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GS-6615
Description: GS-6615 tablet(s) administered orally once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GS-6615
Description: GS-6615 tablet(s) administered orally once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GS-6615
Description: GS-6615 tablet(s) administered orally once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo tablet(s) to match GS-6615 administered orally once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo tablet(s) to match GS-6615 administered orally once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo tablet(s) to match GS-6615 administered orally once daily
Study: NCT02617823

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: lateral position
Description: patients placed on their left side after epidural catheter insertion
Study: NCT01316276

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liposomal amikacin for inhalation
Description: * Liposomal amikacin for inhalation is provided as a sterile aqueous liposomal dispersion for inhalation via nebulization.~* 590 mg of liposomal amikacin for inhalation is administered once daily using the PARI Investigational eFlow® Nebulizer.~* Administration time is approximately 13 minutes.~* Liposomal amikacin for inhalation will be administered in two consecutive extension periods, each consisting of 6 cycles for a total of 12 cycles. Each cycle consists of 28 days on-treatment followed by 28 days off-treatment.
Study: NCT04434690

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Simultaneous bilateral total knee arthroplasty
Description: Two surgeons bilateral TKA group

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Sequenced bilateral TKA
Description: Single surgeon bilateral TKA group
Study: NCT04200807

Intervention type: DEVICE
Intervention: Ultrasound Cardiac Output Monitor (USCOM 1A)
Description: doplerometry with USCOM and echocardiograph is made for assessing central blood flow and spectroscopy with NONIN- for the blood flow in individual peripheral organs (brain and kidney)

Intervention type: DEVICE
Intervention: Ultrasound Cardiac Output Monitor (USCOM 1A)
Description: doplerometry with USCOM and echocardiograph is made for assessing central blood flow and spectroscopy with NONIN- for the blood flow in individual peripheral organs (brain and kidney)

Intervention type: DEVICE
Intervention: Ultrasound Cardiac Output Monitor (USCOM 1A)
Description: doplerometry with USCOM and echocardiograph is made for assessing central blood flow and spectroscopy with NONIN- for the blood flow in individual peripheral organs (brain and kidney)
Study: NCT01126996

Intervention type: PROCEDURE
Intervention: Venepuncture
Description: 1. Venepuncture and blood sample collection in 2010 in a sample of children who received a single dose of a MenC conjugate vaccine at age 1-3 years 10 years earlier.~2. A booster dose of a MenC conjugate vaccine (optional).
Study: NCT02599181

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: propanol-biphenol: Kodan
Description: WITH-group, the skin is disinfected with an aerosolized alcoholic solutionpropanol-biphenol: Kodan, Schülke \& Mayr, Zurich, Switzerland.
Study: NCT02795559

Intervention type: OTHER
Group type: OTHER
Intervention: Glucose
Description: 75g glucose dissolved in 300ml water
Study: NCT03536741

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: General Intravenous Anesthetic
Description: General Intravenous Anesthetic
Study: NCT02755649

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dupilumab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dupilumab
Study: NCT02755649

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Matching Placebo
Study: NCT02547688

Intervention type: DEVICE
Group type: OTHER
Intervention: Nasal High Flow